Close Menu

USPTO

The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.

Split?

Reuters reports that the panel hearing the CRISPR gene editing patent case appears split.

The Broad Institute also announced announced a setback in proceedings over a CRISPR patent application filed in Europe.

Michelle Lee, the director of the United States Patent and Trademark Office, has resigned, IP Watchdog reports.

The University of California is appealing the recent CRISPR/Cas9 patent decision.

The Broad Institute has a shot to end the dispute by early 2017 but the more likely outcome is that the parties will argue over whether to fracture the CRISPR IP estate.

Continuing litigation that began in 2012, Illumina alleges that Qiagen's GeneReader infringes on a patent it holds related to sequencing-by-synthesis technology.

The First Call

The parties involved in the CRISPR patent fight recently held a conference call, Stat News reports.

A patent examiner has issued an Initial Interference Memo in the CRISPR patent fight, possibly leading to an interference proceeding, according to the Law and Biosciences Blog.

The report, which takes a look at patent issues as it relates to confirmatory genetic tests, acknowledged that federal legislation has dramatically changed the landscape in recent years.

Pages

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.